Raloxifene cloridrato

Tu sei qui: Casa / Prodotti chimici farmaceutici / Polveri crude per la perdita di grasso / Raloxifene cloridrato

Top Quality Pharmaceutical Powder Raloxifene Hydrochloride CAS: 82640-04-8

  • fabbricante: Dewael
  • Analisi del prodotto: 99%+
  • Aspetto:light yellow powder
  • Luogo d'origine: Cina
  • Certificazione: SGS,ISO9001, GMP
  • Quantità minima di ordine: 10G
  • Dettagli dell'imballaggio: 1 kg/sacchetto di alluminio,25kg/drum or as your requirements
  • Tempi di consegna: Entro 12 ore dopo aver ricevuto il pagamento
  • Termini di pagamento: Western Union, MoneyGram,Bitcoin,Trasferimento bancario
  • Spedizione: SME,DHL,Fedex,UPS,TNT e così via.
  • Politica: Politica di rispedizione
  • Capacità di fornitura: 500-600kg/mese

Recensioni

Non ci sono ancora recensioni.

Be the first to review “Raloxifene Hydrochloride

Il tuo indirizzo email non verrà pubblicato. I campi richiesti sono contrassegnati *


 

Top Quality Pharmaceutical Powder Raloxifene Hydrochloride CAS: 82640-04-8

 

Dettagli:

Nome:raloxifene hcl, Raloxifene cloridrato
CAS No.:82640-04-8
MF:C28H28ClNO4S
Use:antineoplastic
Aspetto:light yellow powder

 

specificazione:

 

nome del prodotto: Raloxifene cloridrato
CAS: 82640-04-8
MF: C28H28ClNO4S
MW: 510.04
Categorie di prodotti: Active Pharmaceutical Ingredients;Raloxifene;Intracellular receptor;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Pharmaceutical intermediate
Mol File: 82640-04-8.mol
mp 250-253° C
storage temp. -20°C Freezer
solubility DMSO: 28 mg/ml, soluble
form solid
color light yellow
CAS DataBase Reference 82640-04-8(CAS DataBase Reference)
Proprietà chimiche Light-Yellow Solid
uso A nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.

 

Raloxifene Hydrochloride Description:

 

Raloxifene (marketed as Evista) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
This drug is different from hormones (including estrogens and progestins). It works by acting like estrogen (as a selective estrogen receptor modulator or SERM) in some parts of the body. Raloxifene helps to preserve bone mass, but it does not affect the breast and uterus like estrogen or relieve symptoms of menopause such as hot flashes.

 

Raloxifene Hydrochloride Application:

 

Because of Raloxifene’s greater differences in its selectivity of Estrogen agonism and antagonism in different tissues in the body, there is ongoing investigation of its application in other diseases, including prostate cancer, acromegaly, uterine cancer, cardiovascular disease, and breast cancer.
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density.For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate.
Raloxifene is used to prevent and treat bone loss (osteoporosi) in women after menopause. Maintaining strong bones by slowing bone loss helps to reduce the risk of fractures.
Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive) in women after menopause.

 

———————————————————————————————————————————————————————————————————————————————————————-

Contatta ora

 

Il tuo nome (necessario)

La tua email (necessario)

Numero di telefono (necessario)

Soggetto

Il tuo messaggio